MOTS-c and Muscle: The 2024 CK2α Mechanism Breakthrough

Ever since MOTS-c was discovered in 2015, one of the biggest open questions in mitochondrial peptide research has been: how exactly does this 16-amino-acid peptide regulate muscle function? Reynolds et al. had shown in Nature Communications 2021 that physical exercise raises MOTS-c levels in skeletal muscle by a factor of 11.9, and that exogenously administered MOTS-c improves the physical performance of aged mice. The signalling path into the cell remained blurry, however. AMPK activation, folate-AICAR axis, nuclear translocation under stress. Plausible, but with no clear molecular target inside the muscle.

The work by Lu Z et al. 2024 in iScience closes that gap. The group identifies Casein Kinase 2 alpha (CK2α) as a direct binding partner of MOTS-c in skeletal muscle, and it provides human cohort data on top that carries the finding all the way through to human muscle phenotypes.

MOTS-clongevity

Mitochondrial-derived signaling peptide (16 amino acids) that mimics the effects of exercise at the cellular level. Activates AMPK, improves glucose uptake, and enhances fat metabolism - a key tool in metabolic and longevity research.

Background: MOTS-c and the Exercise Paradox (Reynolds 2021)

Before Lu 2024, the evidence picture looked roughly like this. MOTS-c is a peptide of 16 amino acids encoded by the mitochondrial 12S rRNA gene (MT-RNR1). It belongs to the class of mitochondrial-derived peptides (MDPs). Plasma levels decline with age, in type 2 diabetes and in obesity. In animal models, exogenously administered MOTS-c improves glucose homeostasis and physical performance.

Reynolds JC et al. 2021 (Nat Commun, PMID 33473109) showed in their key paper that MOTS-c is exercise-induced. Following a bout of physical exertion, MOTS-c rose up to 11.9-fold in skeletal muscle, with a strong age dependency. The implicit idea: MOTS-c is part of the molecular language by which exercise acts on muscle.

The missing piece was always the same: which muscle protein does MOTS-c actually bind to? Without that answer, the exercise link remained a description, not an explanation.

The Lu 2024 iScience Study: Study Design

Lu Z et al. combine proteomics, biochemical binding analysis and human genetics to decode how MOTS-c acts in muscle. The approach is layered:

1. Target identification: pull-down assays and mass spectrometry to find direct MOTS-c interactors in skeletal muscle.
2. Mechanistic validation: biochemical binding kinetics, enzyme activity assays and cellular loss-of-function experiments on CK2α.
3. Translation: SNP cohorts investigating in human populations whether CK2α-relevant genetic variants correlate with muscle-phenotypic parameters such as the Appendicular Skeletal Muscle Mass Index (ASMI).

This design is the gold standard for mechanism studies. You see not only that something happens, but where, how, and whether it is actually relevant in humans.

Direct CK2α Binding in Skeletal Muscle

The central finding: MOTS-c binds CK2α directly. This is not a diffuse effect through some mysterious intracellular signal. It is a physical peptide-protein interaction. And CK2α is no arbitrary target. Casein Kinase 2 is a ubiquitously expressed, constitutively active serine/threonine kinase with hundreds of known substrates and a prominent role in energy metabolism, cell proliferation and mitochondrial function.

The activation of CK2α by MOTS-c is dose dependent and functional: downstream phosphorylation events and muscle metabolic outputs change depending on how much MOTS-c is available to the system.

SNP Cohort Evidence (A/C Allele, ASMI Reduction)

It gets interesting when Lu 2024 pulls the mechanistic finding into human genetics. The group examined SNP cohorts for variants in the CK2α locus and their association with muscle parameters. The result:

• A/C allele carriers with a functional variant that lowers CK2α activity showed a reduced Appendicular Skeletal Muscle Mass Index (ASMI).
• ASMI is a standardised measure of muscle mass in the arms and legs and is widely used in sarcopenia diagnostics.
• The correlation is not small and, more importantly, it is mechanistically consistent: less CK2α activity means less functional MOTS-c downstream signalling, which empirically translates into less muscle.

Why This Explains the Exercise Link

Here the mechanistic finding gets really interesting. Reynolds 2021 had shown that exercise dramatically raises MOTS-c. Lu 2024 now shows that MOTS-c needs CK2α in order to act in muscle.

Put together, this gives a plausible causal chain:

1. Physical exertion induces MOTS-c expression and secretion in skeletal muscle.
2. MOTS-c binds and activates CK2α in the same or neighbouring muscle cells.
3. CK2α phosphorylates downstream substrates in energy metabolism and mitochondrial communication.
4. The output is improved muscle function, which mirrors exercise-like adaptations in animal models.

This is why MOTS-c is characterised as an exercise-mimetic. The study supplies the molecular substrate for that description. Without CK2α, the peptide is functionally silent. With CK2α, there is a real signalling pathway.

CK2α Biology in Brief: Casein Kinase 2 and Mitochondria-Cell Communication

To situate the Lu finding, one needs a basic understanding of Casein Kinase 2. CK2 is a tetramer made up of two catalytic subunits (CK2α or CK2α') and two regulatory subunits (CK2β). The kinase is:

• Constitutively active and not classically hormonally regulated.
• Responsible for the phosphorylation of hundreds of substrates, including numerous mitochondrial proteins.
• Important for mitochondrial biogenesis and regulation of oxidative phosphorylation.
• Involved in cell survival, stress response and translation.

That MOTS-c should pick CK2α of all kinases as its binding partner is biologically coherent. A mitochondrially encoded peptide that modulates a central node of mitochondrial-nuclear communication fits the concept of retrograde mitochondrion-to-nucleus signalling. On that reading, MOTS-c would be a sensor of the mitochondrial energy state that uses CK2α activation to adjust the transcriptome and phospho-proteome status of muscle to the current metabolic situation.

Broader Implications: Metabolism, Sarcopenia, Aging

Beyond pure mechanism, the CK2α finding has broad implications for three research fields:

Metabolism. CK2α phosphorylates components of glucose and lipid utilisation. When MOTS-c directly modulates CK2α, the insulin sensitisation observed in animal models becomes mechanistically tractable. This fits the 2024 meta-analysis (Diabetol Metab Syndr) showing MOTS-c levels significantly reduced in T2D, gestational diabetes and obesity.

Sarcopenia. The ASMI finding in the human cohort is the first direct link between MOTS-c signalling and age-associated muscle loss in humans. That opens a mechanistically defined target beyond the previously dominant myostatin-inhibitor and anabolic strategies.

Aging in general. MOTS-c declines with age, CK2α activity varies with age and genetic background. The shared axis provides a model for why mitochondrial-muscular output decreases so heterogeneously across the lifespan.

2025 Context: Pancreatic Islets (EMM) + Heart (Front Physiol)

The Lu 2024 work does not stand alone. Two 2025 studies extend the MOTS-c mechanism picture into adjacent tissues:

Pancreatic islet senescence (Experimental & Molecular Medicine 2025, PMID 40855115). The group shows that MOTS-c declines in pancreatic beta cells with age and senescence, and that low plasma MOTS-c levels are associated with type 1 diabetes. MOTS-c slows cellular senescence of islet cells and thereby delays diabetes onset in preclinical models.

Cardiac mitochondria in T2D (Frontiers in Physiology 2025, PMC12257629). Pham et al. administered 15 mg/kg MOTS-c daily for three weeks in a T2D animal model. The result: restored mitochondrial respiration, improved OXPHOS, higher ATP production and reduced cardiac hypertrophy.

What This Means for Peptide Research

For the peptide community, the Lu 2024 finding is an important milestone for several reasons:

• Mechanism instead of description. The era in which MOTS-c was characterised as "activates AMPK somehow" ends here. CK2α is a defined, pharmacologically addressable node.
• Biomarker potential. CK2α activity assays could in future serve as a readout for MOTS-c responsiveness, which is attractive in preclinical screening protocols.
• Combination hypotheses. Anyone combining MOTS-c with other mitochondrial signalling molecules (see SS-31 vs MOTS-c vs NAD+) now has a clearer mechanistic model of which pathways run in parallel and which overlap.
• Individual variance. The A/C allele finding explains why MOTS-c effects in animals and preclinical cohorts may vary. Genetic CK2α variability is one possible explanation.

Conclusion

The Lu Z et al. 2024 iScience study closes a central mechanistic gap in mitochondrial peptide research. In skeletal muscle, MOTS-c binds directly to Casein Kinase 2 alpha and thereby activates a defined signalling pathway for muscle function. The human SNP cohort evidence with A/C allele carriers and reduced ASMI anchors the finding in human muscle biology. Together with the Reynolds 2021 work, a coherent picture emerges of why physical exertion induces MOTS-c and why MOTS-c is so prominently discussed as an exercise-mimetic.

For more details on the product see MOTS-c. For a broader context on mitochondrial signalling molecules, the comparison article Mitochondrial Peptides: SS-31 vs MOTS-c vs NAD+ is a good starting point.

MOTS-clongevity

Mitochondrial-derived signaling peptide (16 amino acids) that mimics the effects of exercise at the cellular level. Activates AMPK, improves glucose uptake, and enhances fat metabolism - a key tool in metabolic and longevity research.